C

Celcuity
D

CELC

13.040
USD
-0.88
(-6.32%)
مغلق
حجم التداول
5,105
الربح لكل سهم
-3
العائد الربحي
-
P/E
-5
حجم السوق
484,169,410
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ADPT
    -0.51000
    (-9.14%)
    5.07000 USD
    A
    ALVR
    0.02740
    (4.88%)
    0.58900 USD
    C
    CELC
    -1.420
    (-10.09%)
    12.650 USD
    D
    DNLI
    -3.400
    (-11.96%)
    25.040 USD
    F
    FGEN
    -0.03530
    (-9.54%)
    0.33460 USD
    I
    IMVT
    -1.440
    (-5.13%)
    26.610 USD
    N
    NERV
    -0.26000
    (-10.88%)
    2.13000 USD
    P
    PLRX
    -0.390
    (-3.04%)
    12.460 USD
    T
    TNXP
    -0.00910
    (-6.53%)
    0.13030 USD
    V
    VCEL
    -0.240
    (-0.46%)
    52.510 USD
    المزيد
الأخبار

العنوان: Celcuity

القطاع: Healthcare
الصناعة: Biotechnology
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic propertiesare highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.